CTD MT 12.5/25/40

Description

CTD-MT 12.5/25/40 Tablet is prescribed for the management of essential hypertension, particularly in patients with stable coronary artery disease. By combining Chlorthalidone, Metoprolol Succinate, and Telmisartan, the tablet offers a comprehensive approach to blood pressure control:

• Chlorthalidone enhances the excretion of sodium and water, decreasing blood volume and pressure.

• Metoprolol Succinate slows the heart rate and reduces the force of contraction, lowering the heart’s oxygen demand.

• Telmisartan blocks the effects of angiotensin II, preventing blood vessel constriction and promoting vasodilation.

Together, these components work synergistically to lower blood pressure, thereby reducing the risk of heart-related complications such as heart attack and stroke.

Dosage and Administration:

The dosage of CTD-MT 12.5/25/40 Tablet is determined by a healthcare provider based on individual patient needs. It is usually taken once daily with or without food. Patients should swallow the tablet whole; it should not be crushed or chewed.

Common Side Effects:

While taking CTD-MT 12.5/25/40 Tablet, patients may experience:

• Headache

• Nausea

• Dizziness

• Stomach upset

• Weakness

These side effects are generally mild and may resolve with continued use. However, if they persist or worsen, medical attention should be sought.

Precautions:

Before starting CTD-MT 12.5/25/40 Tablet, inform your doctor if you have:

• Kidney or liver problems

• A history of heart disease

• Are taking other medications for blood pressure or heart conditions

Avoid excessive alcohol consumption while on this medication, as it may increase the risk of side effects. Regular monitoring of blood pressure and kidney function is recommended.